JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating on August 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Hold rating due to a combination of factors surrounding Cellectis SA’s current and upcoming developments. The company is preparing to present its Phase 1 data and late-stage development strategy for lasme-cel (UCART22) in relapsed/refractory B-ALL at an R&D Day in October 2025. Additionally, Cellectis is on track to initiate a pivotal Phase 2 trial following successful End-of-Phase 1 meetings with the FDA and EMA.
Cellectis also plans to provide a data update for Eti-cel (UCART20x22) from the NATHALI-01 trial in relapsed/refractory NHL in the fourth quarter of 2025. Financially, the company holds approximately $230 million in cash and equivalents as of mid-2025, which is expected to support its operations. However, the estimated annual cash burn and the need for further data updates may contribute to the Hold rating, as investors await more concrete results from these key catalysts.
In another report released on August 6, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.50 price target.